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 Abstract  Leptin, an adipocyte-derived hormone, plays crucial roles in the regulation 
of energy expenditure and food intake. Through analyses of leptin transgenic mice, 
we have demonstrated that leptin has pleiotropic effects such as regulation of insulin 
sensitivity and lipid metabolism. Lipodystrophy is a disease characterized by a lack 
of adipose tissue, which leads to metabolic disorders including insulin resistant 
diabetes, hypertriglyceridemia, and fatty liver. We demonstrated that leptin deﬁ ciency 
plays an important role in the pathogenesis of metabolic disorders in lipodystrophy. 
We also demonstrated the efﬁ cacy of leptin replacement therapy in lipodystrophy. 
Leptin improves insulin sensitivity at least partly by cancellation of lipotoxicity in 
the liver and skeletal muscle. It is also possible that leptin improves insulin secretion 
by cancellation of lipotoxicity in pancreatic beta cells. Using animal models, we 
demonstrated that leptin activates hepatic AMP-activated protein kinase (AMPK), 
and hepatic AMPK activation is involved in the therapeutic effects of leptin. To 
elucidate the pathogenic mechanism of hyperphagia in lipodystrophy, we measured 
food-related neural activity by fMRI and investigated subjective feelings of appe-
tite. We found insufﬁ ciency of postprandial suppression of food-related neural 
activity and formation of satiety feelings in patients with lipodystrophy, which 
might be largely due to leptin deﬁ ciency. In March 2013, marketing and manufac-
turing approval was granted for metreleptin for the treatment of lipodystrophy in 
Japan on the basis of the results of our investigator-initiated trial. This is the ﬁ rst 
global approval of leptin formulation. Leptin has potential as a drug for the treat-
ment of more common metabolic diseases including diabetes, hyperlipidemia, and 
fatty liver. 
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 Introduction 
 Leptin, an adipocyte-derived hormone originally identiﬁ ed from hereditary obese 
mice (ob/ob mice) [ 1 ], plays crucial physiologic roles in the regulation of energy 
expenditure and food intake [ 2 – 6 ]. In obese animals and subjects, plasma leptin 
concentrations are increased in proportion to the degree of adiposity [ 7 – 9 ], indicating 
that leptin is a satiety signal communicating the size of adipose stores to the brain 
[ 10 – 12 ] and that leptin resistance is related to obesity [ 7 ,  13 – 15 ]. Leptin deﬁ ciency 
in human subjects is associated with morbid obesity with insulin resistance, indicating 
the physiological role of leptin in both animal models and humans [ 16 ,  17 ]. Leptin 
is implicated in a number of manifestations seen in obese animal models [ 11 , 
 18 – 21 ]. In this chapter, we introduce our past basic and clinical studies for clinical 
application in lipodystrophy and its related diseases. 
 Transgenic Mice Overexpressing Leptin 
 To explore the clinical implications of leptin in vivo, we generated leptin transgenic 
(LepTg) mice displaying elevated plasma leptin concentrations comparable to those 
seen in obese subjects [ 22 ]. A fusion gene comprising the human SAP promoter 
upstream of the mouse leptin cDNA coding sequences was designed to target hor-
mone expression to the liver [ 23 ,  24 ]. Overexpression of leptin in the liver resulted 
in the complete disappearance of both white adipose tissues in mice [ 22 ]. Such a 
phenotype did not occur when transgene expression was targeted to adipose tissue, 
the endogenous site of leptin production, using adipocyte-speciﬁ c promoters [ 25 ]. 
The hyperleptinemia seen in these LepTg mice provides a unique experimental sys-
tem in which the long-term effects of leptin are investigated in vivo [ 18 – 22 ]. LepTg 
mice exhibit augmented glucose metabolism and increased insulin sensitivity of 
both skeletal muscle and liver [ 22 ], supporting the concept that leptin acts as an 
antidiabetic hormone in vivo [ 26 – 28 ]. These studies suggest the potential useful-
ness of leptin treatment of diabetes and obesity. 
 Crossbreeding Experiment of LepTg Mice with A-ZIPTg Mice 
 Lipodystrophy is a disease characterized by a lack of adipose tissue. It can be 
developed by a genetic abnormality, immune disorder, viral infection, or drugs. 
Irrespective of the etiology, loss of adipose tissue leads to severe insulin-resistant 
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diabetes, hypertriglyceridemia, and fatty liver [ 29 ]. The precise mechanism by 
which this paucity of fat results in these metabolic disorders remains to be elucidated. 
Plasma leptin concentrations are markedly reduced in patients with lipodystrophy 
and in rodent models of lipodystrophy [ 30 – 33 ]. Given leptin’s antidiabetic action, 
leptin deﬁ ciency may play a role in the pathogenesis of metabolic disorders in 
lipodystrophy; thus, leptin may be a drug for patients with lipodystrophy. 
 A mouse model of generalized lipodystrophy (A-ZIPTg mice) was generated by 
expressing in adipose tissue a protein that inactivates basic zipper transcription 
factors [ 32 ]. To assess the pathophysiological role and therapeutic potential of leptin 
in metabolic disorders associated with lipodystrophy, we crossed LepTg mice and 
A-ZIPTg mice to produce doubly transgenic (LepTg/A-ZIPTg) mice virtually lack-
ing adipose tissue and expressing approximately tenfold higher levels of leptin than 
normal controls [ 34 ]. LepTg/A-ZIPTg mice were hypophagic in comparison with 
A-ZIPTg mice and exhibited decreased hepatic steatosis. Glucose and insulin toler-
ance tests displayed increased insulin sensitivity and normal glucose tolerance in 
LepTg/A-ZIPTg mice, which was comparable to LepTg mice. Pair-feeding experi-
ments demonstrated that the effects of leptin were not solely due to decreased food 
intake. These results demonstrate that leptin can improve insulin resistance and dia-
betic manifestations in a mouse model of severe systemic lipodystrophy, indicating 
that leptin is therapeutically useful in the treatment of lipoatrophic diabetes [ 34 ]. 
 Leptin Replacement Therapy in Japanese Patients 
with Lipodystrophy 
 Four-month leptin replacement therapy has been reported to improve glucose and 
lipid metabolism in lipodystrophy patients in the USA [ 35 ]. To elucidate the efﬁ -
cacy, safety, and mechanisms underlying leptin replacement therapy in Asian 
patients with lipodystrophy, we treated seven Japanese patients, two acquired and 
ﬁ ve congenital types, with a physiological replacement dose of leptin [ 36 ,  37 ]. 
Leptin replacement therapy dramatically improved fasting glucose levels (mean ± SE, 
172 ± 20 to 120 ± 12 mg/dl, P < 0.05) and triglyceride levels (mean ± SE, 700 ± 272 to 
260 ± 98 mg/dl, P < 0.05) within 1 week. By 2 months, six of seven patients were 
able to discontinue all antidiabetic drugs, including insulin. 
 To investigate the underlying mechanism of metabolic improvement by leptin, 
we evaluated insulin sensitivity using a hyperinsulinemic euglycemic glucose clamp 
study in human patients (Fig.  1 ). The glucose infusion rate as an index of insulin 
sensitivity was distinctly low at baseline but was improved month by month after 
the initiation of leptin therapy. We also evaluated the glucose tolerance and the abil-
ity of insulin secretion with the oral glucose tolerance test (Fig.  2 ). After 2 months 
of leptin therapy, the glucose level was dramatically improved and, at the same time, 
the ability of insulin secretion was also clearly improved. In lipodystrophy, triglyceride 
accumulates excessively in the cells of non-adipose tissues including the liver and 
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skeletal muscle [ 38 ]. In the liver, the amount of triglyceride accumulation is known to 
be correlated with the severity of insulin resistance [ 39 ]. Triglyceride accumulation 
in skeletal muscle also leads to insulin resistance [ 39 ]. In pancreatic beta cells, 
triglyceride accumulation is known to impair insulin secretion [ 39 ]. Cellular dys-
function caused by ectopic fat deposition has been referred as “lipotoxicity” [ 40 ]. 

































 Fig. 1  Glucose infusion rate in a hyperinsulinemic euglycemic glucose clamp study in 10 patients 
with generalized lipodystrophy. Insulin sensitivity was distinctly low at baseline but improved 
month by month after the initiation of leptin therapy. *p < 0.05 vs baseline 












































 Fig. 2  75 g glucose tolerance test in 10 patients with generalized lipodystrophy at baseline and 2 
months after the initiation of leptin replacement therapy. ( a ) Plasma glucose. ( b ) Insulin levels 
before and after an oral glucose load. Leptin replacement therapy improved glucose tolerance and 
insulin secretion. *p < 0.05 vs baseline 
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leptin improves insulin sensitivity and insulin secretion, we evaluated the tissue 
lipid content in the liver and skeletal muscle in patients with lipodystrophy (Fig.  3 ). 
Liver volume as an index of fatty liver was calculated by computed tomography 
(CT). Leptin therapy effectively decreased liver volume. Skeletal muscle lipid con-
tent was estimated by magnetic resonance imaging (MRI). Skeletal muscle lipid 
content was also signiﬁ cantly decreased after 4 months of leptin therapy. These 
results suggest that leptin improves insulin sensitivity at least partly by cancellation 
of lipotoxicity in the liver and skeletal muscle. Although we did not evaluate lipid 
content in pancreatic beta cells in this study, it is also possible that leptin improves 
insulin secretion by cancellation of lipotoxicity in beta cells.
 We also evaluated subjective feelings of appetite with a 100 mm visual analog 
scale [ 41 ] in patients before and after the initiation of leptin therapy. On this assess-
ment, participants were instructed to rate how hungry they were by marking on a 
scale before and after each meal. A higher score indicated a greater extent of hunger. 
As shown in Fig.  4 , the self-reported hunger scores before meals were not different 
between before and after the initiation of leptin therapy in most patients. In contrast, 
after meals, the score was effectively suppressed after leptin treatment in most 
patients. These results indicate that leptin reinforces the formation of satiety feel-











































 Fig. 3  Ectopic fat deposition in insulin-target tissues. ( a ) Liver volume calculated by CT in 10 
patients with generalized lipodystrophy before and after the initiation of leptin replacement 
therapy. ( b ) Skeletal muscle lipid content estimated by MRI before and 4 months after the initiation 
of leptin replacement therapy. *p < 0.05 vs baseline 
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 Signifi cance of Hepatic AMPK in the Metabolic 
Action of Leptin 
 Leptin effectively improves insulin sensitivity accompanied by dramatic reduction of 
fat content in the liver and skeletal muscle in patients with lipodystrophy [ 35 ,  37 ,  38 ]. 
Using rodent models, it was demonstrated that leptin activates 5′-AMP- activated 
protein kinase (AMPK) in the skeletal muscle through both central and direct 
pathways [ 42 ]. AMPK is a heterotrimeric enzyme that is conserved from yeast to 
humans and functions as a “fuel gauge” to monitor the status of cellular energy. 
AMPK potently stimulates fatty acid oxidation by inhibiting the activity of acetyl-
CoA carboxylase. Thus, AMPK activation by leptin is a plausible mechanism by 
which leptin reduces ectopic fat in the skeletal muscle. In addition to the skeletal 
muscle, recent studies have shown the physiological signiﬁ cance of AMPK in the 
liver [ 43 ,  44 ]. However, the effect of leptin on hepatic AMPK activity remained to 
be determined. The role of AMPK in the pathogenesis of metabolic abnormalities in 
lipodystrophy also remained unclear. We investigated the effect of leptin on hepatic 
AMPK activities and the pathophysiological role of AMPK in A-ZIPTg mice, a 
mouse model of generalized lipodystrophy [ 45 ]. 
 We demonstrated that leptin activates hepatic AMPK through the central nervous 
system and alpha-adrenergic sympathetic nerves. AMPK activities were decreased 
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 Fig. 4  Subjective appetite feelings evaluated with a 100 mm visual analog scale in representative 
patients with generalized lipodystrophy with or without leptin treatment. Patients were treated at 
50 %, 100 %, and 200 % of the replacement dose.  CGL congenital generalized lipodystrophy 
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activities in the liver as well as in skeletal muscle with a signiﬁ cant reduction in 
triglyceride content. Activation of hepatic AMPK with A769662 also led to a 
decrease in hepatic triglyceride content and blood glucose levels in A-ZIP/F-1 mice. 
These results indicate that downregulation of hepatic AMPK activities plays a 
pathophysiological role in the metabolic disturbances of lipodystrophy, and that 
hepatic AMPK activation is involved in the therapeutic effects of leptin. 
 fMRI Analysis of Food-Related Brain Activity in Patients 
with Lipodystrophy 
 Lipodystropic patients also exhibit eating disorders, which makes diet therapy 
difﬁ cult [ 46 ]. Leptin replacement therapy was shown to suppress appetite in lipo-
dystrophic patients [ 46 ,  47 ]. However, there is no report on the comparison of eating 
behaviors between healthy subjects and patients with lipodystrophy. Therefore, the 
pathophysiological role of leptin in eating disorders in patients with lipodystrophy 
remains unclear. From experimental studies in human and animals, it has long been 
established that leptin suppresses energy intake mainly by acting on the hypothala-
mus [ 11 ,  48 ]. However, there is little information about how the neural networks 
including the hypothalamus are inﬂ uenced by leptin signals. Recently the advent of 
functional neuroimaging techniques such as functional magnetic resonance imaging 
(fMRI) has been providing novel insights into homeostatic and hedonic aspects of 
human eating behavior. fMRI measurements of food-related neural activity in con-
genital leptin-deﬁ cient patients were reported [ 49 ]. These analyses revealed that 
leptin treatment modulates neural activity in reward and food-related areas such as 
the ventral striatum and orbitofrontal cortex. 
 To reveal the pathogenic mechanism of eating disorders in lipodystrophic 
patients, we measured food-related neural activity by fMRI scans and investigated 
subjective feelings of appetite under both fasting and postprandial conditions in 
patients and age- and sex-matched healthy subjects [ 51 ]. In addition, we performed 
the same sequential analyses in the same patients with leptin replacement therapy 
[ 51 ]. Although there was little difference in the enhancement of neural activity by 
food stimuli between patients and controls under fasting, postprandial suppression 
of neural activity was insufﬁ cient in many regions of interest including the amyg-
dala, insula, nucleus accumbens, caudate, putamen, and globus pallidus in patients 
compared with controls. Leptin treatment effectively suppressed postprandial neu-
ral activity in many of these regions of interest, whereas it showed little effect under 
fasting in patients. Consistent with these results, postprandial formation of satiety 
feelings was insufﬁ cient in patients compared with controls, which was effectively 
reinforced by leptin treatment. These results demonstrate the insufﬁ ciency of post-
prandial suppression of food-related neural activity and formation of satiety feelings 
in patients with lipodystrophy, which might be largely due to leptin deﬁ ciency. This 
study also demonstrated that leptin has little involvement in the regulation of neural 
activity and eating behavior under fasting, whereas leptin plays a signiﬁ cant role in 
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these regulations under postprandial conditions. We found that leptin suppressed 
neural activity in regions involved in the reward system such as the amygdala, 
hippocampus, NcA, and caudate. Further study is needed to elucidate the role of the 
reward system on appetite regulation by leptin. 
 Conclusions 
 Metreleptin is an analog of human leptin originally developed by Amgen and has 
been used for treatment in patients with lipodystrophy also in Japan. In July 2012, 
Shionogi originally ﬁ led a New Drug Application (NDA), which was based on the 
results of our investigator-initiated trial conducted by the Kyoto University Graduate 
School of Medicine with assistance from the Translational Research Center (the 
current Institute for Advancement of Clinical and Translational Science) at Kyoto 
University Hospital. In March 2013, marketing and manufacturing approval was 
granted by the Japanese Ministry of Health, Labour and Welfare for subcutaneous 
metreleptin for the treatment of lipodystrophy. This is the ﬁ rst global approval of 
leptin formulation [ 51 ]. In patients with lipodystrophy, leptin improved insulin 
resistance, hypertriglyceridemia, and fatty liver. We have demonstrated the thera-
peutic usefulness of leptin in insulin-deﬁ cient diabetes, non-obese type 2 diabetes, 
type 2 diabetes with mild obesity, hypertriglyceridemia, and non-alcoholic fatty 
liver [ 45 ,  52 – 56 ]. Leptin has potential as a drug for the treatment of more common 
metabolic diseases including diabetes, hyperlipidemia, and fatty liver. 
 References 
  1.  Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning 
of the mouse obese gene and its human homologue. Nature 372:425–432 
  2.  Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 
395:763–770 
  3.  Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F (1995) 
Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540–543 
  4.  Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley 
SK, Friedman JM (1995) Weight-reducing effects of the plasma protein encoded by the obese 
gene. Science 269:543–546 
  5.  Campﬁ eld LA, Smith FJ, Guisez Y, Devos R, Burn P (1995) Recombinant mouse OB protein: 
evidence for a peripheral signal linking adiposity and central neural networks. Science 
269:546–549 
  6.  Satoh N, Ogawa Y, Katsuura G, Numata Y, Tsuji T, Hayase M, Ebihara K, Masuzaki H, Hosoda 
K, Yoshimasa Y et al (1999) Sympathetic activation of leptin via the ventromedial hypothala-
mus: leptin-induced increase in catecholamine secretion. Diabetes 48:1787–1793 
Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited.
K. Ebihara and K. Nakao
173
  7.  Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS (1995) Leptin levels 
reﬂ ect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat 
Med 1:1311–1314 
  8.  Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, 
Ranganathan S et al (1995) Leptin levels in human and rodent: measurement of plasma leptin 
and ob RNA in obese and weight-reduced subjects. Nat Med 1:1155–1161 
  9.  Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, 
Marco CC, McKee LJ, Bauer TL et al (1996) Serum immunoreactive-leptin concentrations in 
normal-weight and obese humans. N Engl J Med 334:292–295 
 10.  Isse N, Ogawa Y, Tamura N, Masuzaki H, Mori K, Okazaki T, Satoh N, Shigemoto M, 
Yoshimasa Y, Nishi S et al (1995) Structural organization and chromosomal assignment of the 
human obese gene. J Biol Chem 270:27728–27733 
 11.  Satoh N, Ogawa Y, Katsuura G, Tsuji T, Masuzaki H, Hiraoka J, Okazaki T, Tamaki M, 
Hayase M, Yoshimasa Y et al (1997) Pathophysiological signiﬁ cance of the obese gene product, 
leptin, in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety 
effect in VMH-lesioned rats. Endocrinology 138:947–954 
 12.  Imagawa K, Numata Y, Katsuura G, Sakaguchi I, Morita A, Kikuoka S, Matumoto Y, Tsuji T, 
Tamaki M, Sasakura K et al (1998) Structure–function studies of human leptin. J Biol Chem 
273:35245–35249 
 13.  Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, 
Zhang PL, Sinha MK, Considine RV (1996) Decreased cerebrospinal-ﬂ uid/serum leptin ratio 
in obesity: a possible mechanism for leptin resistance. Lancet 348:159–161 
 14.  Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM (1997) 
Physiological response to long-term peripheral and central leptin infusion in lean and obese 
mice. Proc Natl Acad Sci U S A 94:8878–8883 
 15.  Tanaka T, Masuzaki H, Yasue S, Ebihara K, Shiuchi T, Ishii T, Arai N, Hirata M, 
Yamamoto H, Hayashi T et al (2007) Central melanocortin signaling restores skeletal 
muscle AMP- activated protein kinase phosphorylation in mice fed a high-fat diet. Cell Metab 
5:395–402 
 16.  Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby 
JE, Mohammed SN, Hurst JA et al (1997) Congenital leptin deﬁ ciency is associated with 
severe early-onset obesity in humans. Nature 387:903–908 
 17.  Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD (1998) A leptin missense mutation asso-
ciated with hypogonadism and morbid obesity. Nat Genet 18:213–215 
 18.  Yura S, Ogawa Y, Sagawa N, Masuzaki H, Itoh H, Ebihara K, Aizawa-Abe M, Fujii S, Nakao 
K (2000) Accelerated puberty and late-onset hypothalamic hypogonadism in female trans-
genic skinny mice overexpressing leptin. J Clin Invest 105:749–755 
 19.  Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, 
Hosoda K, Inoue G et al (2000) Pathophysiological role of leptin in obesity-related hyperten-
sion. J Clin Invest 105:1243–1252 
 20.  Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N, Kim CA, Ogawa Y, Liu X, Ware SM, 
Craigen WJ et al (2004) Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci U 
S A 101:3258–3263 
 21.  Suganami T, Mukoyama M, Mori K, Yokoi H, Koshikawa M, Sawai K, Hidaka S, Ebihara K, 
Tanaka T, Sugawara A et al (2005) Prevention and reversal of renal injury by leptin in a new 
mouse model of diabetic nephropathy. FASEB J 19:127–129 
 22.  Ogawa Y, Masuzaki H, Hosoda K, Aizawa-Abe M, Suga J, Suda M, Ebihara K, Iwai H, 
Matsuoka N, Satoh N et al (1999) Increased glucose metabolism and insulin sensitivity in 
transgenic skinny mice overexpressing leptin. Diabetes 48:1822–1829 
 23.  Ogawa Y, Itoh H, Tamura N, Suga S, Yoshimasa T, Uehira M, Matsuda S, Shiono S, Nishimoto 
H, Nakao K (1994) Molecular cloning of the complementary DNA and gene that encode 
mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain 
natriuretic peptide gene. J Clin Invest 93:1911–1921 
Translational Research of Leptin in Lipodystrophy and Its Related Diseases
174
 24.  Masuzaki H, Ogawa Y, Isse N, Satoh N, Okazaki T, Shigemoto M, Mori K, Tamura N, 
Hosoda K, Yoshimasa Y et al (1995) Human obese gene expression. Adipocyte-speciﬁ c expres-
sion and regional differences in the adipose tissue. Diabetes 44:855–858 
 25.  Ioffe E, Moon B, Connolly E, Friedman JM (1998) Abnormal regulation of the leptin gene in 
the pathogenesis of obesity. Proc Natl Acad Sci U S A 95:11852–11857 
 26.  Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ (1997) Acute stimulation of 
glucose metabolism in mice by leptin treatment. Nature 389:374–377 
 27.  Liu L, Karkanias GB, Morales JC, Hawkins M, Barzilai N, Wang J, Rossetti L (1998) 
Intracerebroventricular leptin regulates hepatic but not peripheral glucose ﬂ uxes. J Biol Chem 
273:31160–31167 
 28.  Cusin I, Zakrzewska KE, Boss O, Muzzin P, Giacobino JP, Ricquier D, Jeanrenaud B, 
Rohner- Jeanrenaud F (1998) Chronic central leptin infusion enhances insulin-stimulated 
glucose metabolism and favors the expression of uncoupling proteins. Diabetes 47:1014–1019 
 29.  Goldstein BJ (1994) Syndrome of extreme insulin resistance. In: Kahn CR, Weir GC (eds) 
Joslin’s diabetes mellitus. Lea & Febiger, Philadelphia 
 30.  Andreelli F, Hanaire-Broutin H, Laville M, Tauber JP, Riou JP, Thivolet C (2000) Normal 
reproductive function in leptindeﬁ cient patients with lipoatrophic diabetes. J Clin Endocrinol 
Metab 85:715–719 
 31.  Pardini VC, Victoria IM, Rocha SM, Andrade DG, Rocha AM, Pieroni FB, Milagres G, 
Purisch S, Velho G (1998) Leptin levels, beta-cell function, and insulin sensitivity in families 
with congenital and acquired generalized lipoatrophic diabetes. J Clin Endocrinol Metab 
83:503–508 
 32.  Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, 
Lee E, Aoyama T, Eckhaus M et al (1998) Life without white fat: a transgenic mouse. Genes 
Dev 12:3168–3181 
 33.  Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, Brown MS 
(1998) Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear 
SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 
12:3182–3194 
 34.  Ebihara K, Ogawa Y, Masuzaki H, Shintani M, Miyanaga F, Aizawa-Abe M, Hayashi T, 
Hosoda K, Inoue G, Yoshimasa Y et al (2001) Transgenic overexpression of leptin rescues 
insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 
50:1440–1448 
 35.  Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, 
Reitman ML, Taylor SI et al (2002) Leptin-replacement therapy for lipodystrophy. N Engl J 
Med 346:570–578 
 36.  Ebihara K, Masuzaki H, Nakao K (2004) Long-term leptinreplacement therapy for lipoatrophic 
diabetes. N Engl J Med 351:615–616 
 37.  Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, Tanaka T, Chusho H, 
Miyazawa T, Hayashi T et al (2007) Efﬁ cacy and safety of leptin-replacement therapy and 
possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin 
Endocrinol Metab 92:532–541 
 38.  Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor 
SI, Gorden P et al (2002) Leptin reverses insulin resistance and hepatic steatosis in patients 
with severe lipodystrophy. J Clin Invest 109:1345–1350 
 39.  Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106:171–176 
 40.  Unger RH (1995) Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and 
clinical implications. Diabetes 44:863–870 
 41.  Chaput JP, Gilbert JA, Gregersen NT, Pedersen SD, Sjödin AM (2010) Comparison of 150- mm 
versus 100-mm visual analogue scales in free living adult subjects. Appetite 49:691–695 
 42.  Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Müller C, Carling D, Kahn BB (2002) Leptin 
stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 
415:339–343 
K. Ebihara and K. Nakao
175
 43.  Assiﬁ  MM, Suchankova G, Constant S, Prentki M, Saha AK, Ruderman NB (2005) 
AMP- activated protein kinase and coordination of hepatic fatty acid metabolism of starved/
carbohydrate- refed rats. Am J Physiol Endocrinol Metab 289:E794–E800 
 44.  Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley 
LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of 
metformin. Science 310:1642–1646 
 45.  Miyamoto L, Ebihara K, Kusakabe T, Aotani D, Yamamoto-Kataoka S, Sakai T, Aizawa-Abe 
M, Yamamoto Y, Fujikura J, Hayashi T et al (2012) Leptin activates hepatic 5ʹ-AMP-activated 
protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential 
mechanism for improvement of fatty liver in lipodystrophy by leptin. J Biol Chem 
287:40441–40447 
 46.  McDufﬁ e JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, Yanovski JA (2004) 
Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin 
insufﬁ ciency. J Clin Endocrinol Metab 89:4258–4263 
 47.  Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, Premkumar A, Depaoli 
AM, Skarulis MC, Oral EA et al (2004) Changes in body composition in patients with severe 
lipodystrophy after leptin replacement therapy. Metabolism 53:513–519 
 48.  Schwartz MW, Seeley RJ, Campﬁ eld LA, Burn P, Baskin DG (1996) Identiﬁ cation of targets 
of leptin action in rat hypothalamus. J Clin Invest 98:1101–1106 
 49.  Farooqi IS, Bullmore E, Keogh J, Gillard J, O’Rahilly S, Fletcher PC (2007) Leptin regulates 
striatal regions and human eating behavior. Science 317:1355 
 50.  Aotani D, Ebihara K, Sawamoto N, Kusakabe T, Aizawa-Abe M, Kataoka S, Sakai T, 
Iogawa H, Ebihara C, Fujikura J et al (2012) Functional magnetic resonance imaging analysis 
of food- related brain activity in patients with lipodystrophy undergoing leptin replacement 
therapy. J Clin Endocrinol Metab 97:3663–3671 
 51.  Chou K, Perry CM (2013) Metreleptin: ﬁ rst global approval. Drugs 73:989–997 
 52.  Miyanaga F, Ogawa Y, Ebihara K, Hidaka S, Tanaka T, Hayashi S, Masuzaki H, Nakao K 
(2003) Leptin as an adjunct of insulin therapy in insulin-deﬁ cient diabetes. Diabetologia 
4610:1329–1337 
 53.  Naito M, Fujikura J, Ebihara K, Miyanaga F, Yokoi H, Kusakabe T, Yamamoto Y, Son C, 
Mukoyama M, Hosoda K et al (2011) Therapeutic impact of leptin on diabetes, diabetic com-
plications, and longevity in insulin-deﬁ cient diabetic mice. Diabetes 60:2265–2273 
 54.  Kusakabe T, Tanioka H, Ebihara K, Hirata M, Miyamoto L, Miyanaga F, Hige H, Aotani D, 
Fujisawa T, Masuzaki H et al (2009) Beneﬁ cial effects of leptin on glycaemic and lipid control 
in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a 
high-fat diet. Diabetologia 52:675–683 
 55.  Matsuoka N, Ogawa Y, Masuzaki H, Ebihara K, Aizawa-Abe M, Satoh N, Ishikawa E, 
Fujisawa Y, Kosaki A, Yamada K et al (2001) Decreased triglyceride-rich lipoproteins in trans-
genic skinny mice overexpressing leptin. Am J Physiol Endocrinol Metab 280:E334–E339 
 56.  Yamamoto-Kataoka S, Ebihara K, Aizawa-Abe M, Nishio M, Kusakabe T, Yamamoto Y, 
Aotani D, Sakai T, Zhao M, Ebihara C et al (2014) Leptin improves fatty liver independently 
of insulin sensitization and appetite suppression in hepatocyte-speciﬁ c Pten-deﬁ cient mice 
with insulin hypersensitivity. Horm Metab Res (in press) 
Translational Research of Leptin in Lipodystrophy and Its Related Diseases
